Craig Mayer, Nick WIlliams, Vojtech Huser
Lister Hill National Center for Biomedical Communications, National Library of Medicine, NIH, Bethesda, MD

See the full regCTG repository at https://github.com/lhncbc/CRI/tree/master/regCTG

To return to the list of conditions and view other reports go to https://lhncbc.github.io/CRI/regCTG/regCTG-condition_report_links.html


Study Counts

Type Study_count
Total_Studies 120
interventional 105
Observational 13
Registry 2

Studies over Time by Start Date

```

Interventional Trials

Intervention Type

intervention_type Study_Count
Drug 65
Drug|Other 7
Biological|Drug 6
Biological 4
Drug|placebo 4
Other 4
Biological|Drug|Other 2
Device 2
Drug|Procedure 2
Behavioral|Drug 1
Behavioral|Other 1
Biological|Other 1
Biological|Other|Radiation 1
Biological|Procedure 1
Biological|Radiation 1
Drug|Other|Procedure 1
Other|Procedure 1
Radiation 1

Count of Studies by Intervention (normalized and mapped)

Interventions over Time

Yearly studies for each intervention by start date

Studies by Country

Country Study_Count
United States 53
Canada 7
France 6
Italy 5
China 4
Germany 2
Korea, Republic of 2
Taiwan 2
United States|Canada 2
Australia 1
Australia|Austria|Belgium|Brazil|Bulgaria|Canada|China|Czechia|Denmark|Finland|Germany|Greece|India|Israel|Italy|Korea, Republic of|Poland|Russian Federation|Sweden|United Kingdom 1
Austria|Germany|Netherlands|Poland|Slovenia 1
Belgium|Denmark|France|Germany|Italy|Netherlands|Poland|Spain|United Kingdom 1
Denmark 1
Denmark|France|Germany|Greece|Italy|Netherlands|Spain|Sweden|United Kingdom 1
Japan 1
NA 1
Netherlands 1
Netherlands|Australia|Canada|Croatia|France|Hungary|Israel|Italy|Korea, Republic of|Poland|Romania|Russian Federation|Spain|Sweden 1
Norway 1
Spain 1
United Kingdom 1
United States|Argentina|Australia|Belgium|Canada|France|Germany|Italy|Netherlands|Spain|Sweden 1
United States|Australia|Austria|Belgium|Brazil|Canada|Czechia|Denmark|France|Germany|Hungary|India|Italy|Korea, Republic of|Mexico|Netherlands|Poland|Portugal|Romania|Russian Federation|Serbia|Spain|Sweden|Switzerland 1
United States|Australia|Austria|Belgium|Canada|France|Germany|Italy|Japan|Netherlands|Spain|Sweden|United Kingdom 1
United States|Australia|Belgium|Brazil|Canada|China|Czechia|France|Germany|Greece|India|Israel|Italy|Japan|Korea, Republic of|Netherlands|Poland|Russian Federation|Spain|United Kingdom 1
United States|Australia|Canada|Denmark|France|Germany|Hong Kong|Israel|Italy|Japan|Korea, Republic of|Singapore|Spain|Switzerland|Taiwan|United Kingdom 1
United States|Australia|Canada|Italy|Netherlands|Romania|Spain|Switzerland 1
United States|Australia|China|Singapore|Taiwan 1
United States|Belgium|China|France|Germany|Hong Kong|Italy|Korea, Republic of|Netherlands|Singapore|Spain|Taiwan|United Kingdom 1
United States|United Kingdom 1

Sites per Study

Site_count Study_Count
1 46
2 4
3 10
4 2
5 6
6 1
7 2
8 1
9 4
10 1
13 2
17 2
19 1
22 1
23 1
27 2
28 1
34 1
37 1
38 1
50 1
54 1
61 1
66 1
84 2
86 1
140 1
143 1
394 1
405 1
428 1
508 1
663 1
938 1

Phase

Phase Study_Count
Phase 2 74
Phase 1/Phase 2 10
Phase 1 8
N/A 6
Phase 3 3
Phase 2/Phase 3 2
Early Phase 1 1
Phase 4 1

Number of Arms

Number_of_Arms Count_of_Studies
1 66
2 26
3 3
4 2
5 1
NA 7

Enrollment Metrics by Phase

Measure Early.Phase.1 N.A Phase.1 Phase.1.Phase.2 Phase.2 Phase.2.Phase.3 Phase.3 Phase.4
Min. 12 30.0 12.00 10.0 4.00000 91.00 205.0000 250
1st Qu. 12 87.5 18.25 19.0 30.00000 152.25 302.5000 250
Median 12 170.0 27.50 80.0 52.00000 213.50 400.0000 250
Mean 12 163.0 47.75 211.7 90.28767 213.50 347.3333 250
3rd Qu. 12 236.0 46.50 217.5 120.00000 274.75 418.5000 250
Max. 12 290.0 154.00 970.0 818.00000 336.00 437.0000 250

Trial Group Type

group_type Group_Count
Experimental 122
Active Comparator 12
NA 7
No Intervention 3
Placebo Comparator 2
Other 1

Intervention Model

intervention_model Study_Count
Single Group Assignment 72
Parallel Assignment 27
Sequential Assignment 3
NA 2
Crossover Assignment 1

Primary Purpose

primary_purpose Study_Count
Treatment 96
Diagnostic 5
Supportive Care 2
Health Services Research 1
NA 1

Observational Studies

Studies by Country

Country Study_Count
United States 4
NA 2
United Kingdom 2
Belgium|France|Germany|Italy|Luxembourg|Netherlands|Spain|United Kingdom 1
France 1
Korea, Republic of 1
Poland 1
Slovenia 1

Sites per Study

Site_count Study_Count
1 10
7 1
28 1
30 1

Enrollment Metrics

Measure Observational
Min 3.0000
1st Qu 48.0000
Median 80.0000
Mean 227.1538
3rd Qu 150.0000
Max 2030.0000

Observation Model

observational_model Study_Count
Cohort 9
Case-Only 3
NA 1

Time Perspective

time_perspective Study_Count
Prospective 8
Retrospective 4
Other 1

Registries

Studies by Country

Country Study_Count
United States 2

Sites per Study

Site_count Study_Count
1 2

Enrollment Metrics

Measure Registries
Min 100.0
1st Qu 1762.5
Median 3425.0
Mean 3425.0
3rd Qu 5087.5
Max 6750.0

Registry Model

observational_model Study_Count
Case-Only 1
Cohort 1

Time Perspective

time_perspective Study_Count
Prospective 2

Follow-up

target_duration Study_Count
15 Years 1
5 Years 1

Overview of Studies

Interventional Trials

#If less then 500 trials

nct_id brief_title link overall_status source primary_completion_date
NCT01896479 A Study of Two Different Doses of Cabozantinib (XL184) in Progressive, Metastatic Medullary Thyroid Cancer https://ClinicalTrials.gov/show/NCT01896479 Active, not recruiting Exelixis 2020-09-30
NCT04211337 A Study of Selpercatinib (LY3527723) in Participants With RET-Mutant Medullary Thyroid Cancer https://ClinicalTrials.gov/show/NCT04211337 Recruiting Eli Lilly and Company 2023-02-17
NCT03736720 Liposomal Irinotecan, Fluorouracil and Leucovorin in Treating Patients With Refractory Advanced High Grade Neuroendocrine Cancer of Gastrointestinal, Unknown, or Pancreatic Origin https://ClinicalTrials.gov/show/NCT03736720 Recruiting Roswell Park Cancer Institute 2021-09-05
NCT03333616 Nivolumab Combined With Ipilimumab for Patients With Advanced Rare Genitourinary Tumors https://ClinicalTrials.gov/show/NCT03333616 Recruiting Dana-Farber Cancer Institute 2021-05-31
NCT03279614 Study to Evaluate the Efficiency of SOX as Seconde-line Chemotherapy in Neuroendocrine Carcinoma https://ClinicalTrials.gov/show/NCT03279614 Recruiting Peking University 2019-09-01
NCT03278405 Avelumab in G3 NEC https://ClinicalTrials.gov/show/NCT03278405 Completed Sunnybrook Health Sciences Centre 2019-08-09
NCT03246659 Radiolabelled CCK-2/Gastrin Receptor Analogue for Personalized Theranostic Strategy in Advanced MTC https://ClinicalTrials.gov/show/NCT03246659 Completed Azienda Ospedaliero, Universitaria Pisana 2018-11-30
NCT03147404 Phase II Study of Avelumab in Metastatic Gastronetro-pancreatic (GEP) Neuroendocrine Carcinoma (NEC, WHO Grade 3) as Second-line Treatment After Failing to Etoposide+Cisplatin: Integration of Genomic Analysis to Identify Predictive Molecular Subtypes https://ClinicalTrials.gov/show/NCT03147404 Completed Samsung Medical Center 2019-07-22
NCT03110978 Stereotactic Body Radiation Therapy With or Without Nivolumab in Treating Patients With Stage I-IIA or Recurrent Non-small Cell Lung Cancer https://ClinicalTrials.gov/show/NCT03110978 Recruiting M.D. Anderson Cancer Center 2022-06-30
NCT03079440 TEMCAP in Grade 3 and Low Ki-67 Gastroenteropancreatic Neuroendocrine Tumors https://ClinicalTrials.gov/show/NCT03079440 Recruiting Asan Medical Center 2020-12-31
NCT03074513 Atezolizumab and Bevacizumab in Treating Patients With Rare Solid Tumors https://ClinicalTrials.gov/show/NCT03074513 Recruiting M.D. Anderson Cancer Center 2021-03-31
NCT03072160 Pembrolizumab in Recurrent or Metastatic Medullary Thyroid Cancer https://ClinicalTrials.gov/show/NCT03072160 Completed National Institutes of Health Clinical Center (CC) 2019-11-22
NCT03037385 Phase 1/2 Study of the Highly-selective RET Inhibitor, Pralsetinib (BLU-667), in Patients With Thyroid Cancer, Non-Small Cell Lung Cancer, and Other Advanced Solid Tumors https://ClinicalTrials.gov/show/NCT03037385 Recruiting Blueprint Medicines Corporation 2021-12-31
NCT03012620 Secured Access to Pembrolizumab for Patients With Selected Rare Cancer Types https://ClinicalTrials.gov/show/NCT03012620 Recruiting UNICANCER 2023-01-31
NCT02955069 Study of Efficacy and Safety of PDR001 in Patients With Advanced or Metastatic, Well-differentiated, Non-functional Neuroendocrine Tumors of Pancreatic, Gastrointestinal (GI), or Thoracic Origin or Poorly-differentiated Gastroenteropancreatic Neuroendocrine Carcinoma (GEP-NEC) https://ClinicalTrials.gov/show/NCT02955069 Completed Novartis 2018-08-10
NCT02936323 PEN-221 in Somatostatin Receptor 2 Expressing Advanced Cancers Including Neuroendocrine and Small Cell Lung Cancers https://ClinicalTrials.gov/show/NCT02936323 Active, not recruiting Tarveda Therapeutics 2020-07-31
NCT02856347 Prospective Study Evaluating the Medullary Thyroid Cancer Management’s Care Using PET F-DOPA in Patients With a High Level of Postoperative Residual Thyrocalcitonin https://ClinicalTrials.gov/show/NCT02856347 Recruiting Institut Claudius Regaud 2021-04-30
NCT02820857 Assessment of the Efficacy of Bevacizumab in Combination With Folfiri as Second-line Treatment in Patients Suffering From an Advanced Inoperable Poorly Differentiated Neuroendocrine Carcinoma of an Unknown or Gastroentero-pancreatic Primary Cancer https://ClinicalTrials.gov/show/NCT02820857 Recruiting Hospices Civils de Lyon 2023-03-04
NCT02806648 A Trial to Assess the Activity and Safety of Palbociclib in Patients With Well and Moderately Differentiated Metastatic Pancreatic Neuroendocrine Tumors (pNET) https://ClinicalTrials.gov/show/NCT02806648 Completed Grupo Espanol de Tumores Neuroendocrinos 2017-07-31
NCT02755675 uPAR-PET for Prognostication in Patients With Non-small Cell Lung Cancer, Malignant Pleural Mesothelioma and Large Cell Neuroendocrine Carcinoma of the Lung https://ClinicalTrials.gov/show/NCT02755675 Recruiting Rigshospitalet, Denmark 2023-04-30
NCT02754297 Personalized PRRT of Neuroendocrine Tumors https://ClinicalTrials.gov/show/NCT02754297 Recruiting CHU de Quebec-Universite Laval 2021-04-30
NCT02695459 Cisplatinum and Everolimus in Patients With Metastatic or Unresectable NEC of Extrapulmonary Origin https://ClinicalTrials.gov/show/NCT02695459 Recruiting The Netherlands Cancer Institute 2020-06-30
NCT02687958 Study of Everolimus as Maintenance Therapy for Metastatic NEC With Pulmonary or Gastroenteropancreatic Origin https://ClinicalTrials.gov/show/NCT02687958 Recruiting Gruppo Oncologico Italiano di Ricerca Clinica 2021-12-31
NCT02595424 Cisplatin, Carboplatin and Etoposide or Temozolomide and Capecitabine in Treating Patients With Neuroendocrine Carcinoma of the Gastrointestinal Tract or Pancreas That Is Metastatic or Cannot Be Removed by Surgery https://ClinicalTrials.gov/show/NCT02595424 Recruiting Eastern Cooperative Oncology Group 2024-01-01
NCT02586350 Study of Anlotinib in Patients With Medullary Thyroid Carcinoma(ALTER01031) https://ClinicalTrials.gov/show/NCT02586350 Completed Chia Tai Tianqing Pharmaceutical Group Co., Ltd. 2018-09-30
NCT02834013 Nivolumab and Ipilimumab in Treating Patients With Rare Tumors https://ClinicalTrials.gov/show/NCT02834013 Recruiting National Cancer Institute (NCI) 2021-08-31
NCT01229943 Everolimus and Octreotide Acetate With or Without Bevacizumab in Treating Patients With Locally Advanced or Metastatic Pancreatic Neuroendocrine Tumors That Cannot Be Removed by Surgery https://ClinicalTrials.gov/show/NCT01229943 Active, not recruiting National Cancer Institute (NCI) 2014-09-01
NCT02893930 Sapanisertib in Treating Patients With Metastatic or Refractory Pancreatic Neuroendocrine Tumor That Cannot Be Removed by Surgery https://ClinicalTrials.gov/show/NCT02893930 Active, not recruiting National Cancer Institute (NCI) 2020-07-31
NCT03387592 CAPTEM or FOLFIRI as SEcond-line Therapy in NEuroendocrine CArcinomas https://ClinicalTrials.gov/show/NCT03387592 Recruiting Istituto Scientifico Romagnolo per lo Studio e la cura dei Tumori 2022-01-31
NCT02457273 Phase II Study to Evaluate the Efficacy and Safety of TLC388 for Differentiated Neuroendocrine Carcinomas Patients https://ClinicalTrials.gov/show/NCT02457273 Completed National Health Research Institutes, Taiwan 2018-04-18
NCT02318784 Carfilzomib for the Treatment of Patients With Advanced Neuroendocrine Cancers https://ClinicalTrials.gov/show/NCT02318784 Active, not recruiting SCRI Development Innovations, LLC 2020-02-01
NCT02315625 Study of Mutation-Targeted Therapy With Sunitinib or Everolimus in People With Advanced Low- or Intermediate-Grade Neuroendocrine Tumors of the Gastrointestinal Tract and Pancreas With or Without Cytoreductive Surgery https://ClinicalTrials.gov/show/NCT02315625 Completed National Institutes of Health Clinical Center (CC) 2019-05-22
NCT02250885 KPT-330 to Treat Poorly Differentiated Lung and Gastroenteropancreatic Tumors https://ClinicalTrials.gov/show/NCT02250885 Completed Gabrail Cancer Center Research 2016-08-31
NCT02248012 Everolimus and Temozolomide in Advanced Gastroenteropancreatic Neuroendocrine Carcinoma (G3) https://ClinicalTrials.gov/show/NCT02248012 Completed Haukeland University Hospital 2018-01-31
NCT02236910 An Open Label Registry Study of Lutetium-177 (DOTA0, TYR3) Octreotate (Lu-DOTA-TATE) Treatment in Patients With Somatostatin Receptor Positive Tumours https://ClinicalTrials.gov/show/NCT02236910 Recruiting Lawson Health Research Institute 2021-09-30
NCT02230176 Antitumor Efficacy of Peptide Receptor Radionuclide Therapy With 177Lutetium -Octreotate Randomized vs Sunitinib in Unresectable Progressive Well-differentiated Neuroendocrine Pancreatic Tumor: First Randomized Phase II https://ClinicalTrials.gov/show/NCT02230176 Recruiting Gustave Roussy, Cancer Campus, Grand Paris 2023-10-31
NCT02215447 A Feasibility Study Of NAB-Paclitaxel In Combination With Carboplatin As First Line Treatment Of Gastrointestinal Neuroendocrine Carcinomas https://ClinicalTrials.gov/show/NCT02215447 Active, not recruiting Barwon Health 2018-11-30
NCT02113800 Safety and Tolerability of Everolimus as Second-line Treatment in Poorly Differentiated Neuroendocrine Carcinoma / Neuroendocrine Carcinoma G3 (WHO 2010) and Neuroendocrine Tumor G3 - an Investigator Initiated Phase II Study https://ClinicalTrials.gov/show/NCT02113800 Recruiting AIO-Studien-gGmbH 2019-09-30
NCT02101918 Ziv-Aflibercept in Treating and Computed Tomography Perfusion Imaging in Predicting Response in Patients With Pancreatic Neuroendocrine Tumors That Are Metastatic or Cannot Be Removed by Surgery https://ClinicalTrials.gov/show/NCT02101918 Completed National Cancer Institute (NCI) 2018-01-31
NCT01298323 Study to Determine if Contacting Patients With MTC More Frequently Results in Earlier Detection and Treatment of Signs and Symptoms of AEs and Thus a Decrease in the Percentage of Time Patients Experience AEs During First 12 Months on Vandetanib Treatment https://ClinicalTrials.gov/show/NCT01298323 Active, not recruiting Sanofi 2013-04-30
NCT03136055 Pembrolizumab-based Therapy in Previously Treated High Grade Neuroendocrine Carcinomas https://ClinicalTrials.gov/show/NCT03136055 Recruiting University of California, San Francisco 2022-02-28
NCT03352934 Avelumab Treatment in Patients With Neuroendocrine Carcinomas (NEC G3) Progressive After Chemotherapy https://ClinicalTrials.gov/show/NCT03352934 Recruiting Johannes Gutenberg University Mainz 2023-01-31
NCT01876771 A Trial to Assess the Safety and Effectiveness of Lutetium-177 Octreotate Therapy in Neuroendocrine Tumours https://ClinicalTrials.gov/show/NCT01876771 Recruiting AHS Cancer Control Alberta 2033-12-31
NCT01873248 Investigation of 68Ga-DOTATATE, as a PET Imaging Agent in Neuroendocrine Tumor Patients https://ClinicalTrials.gov/show/NCT01873248 Completed Jonsson Comprehensive Cancer Center 2017-06-16
NCT01866228 Clinical Trial of the Impact of Treatment Consultation Recordings on Cancer Patient Outcomes https://ClinicalTrials.gov/show/NCT01866228 Completed University of Manitoba 2017-02-28
NCT01856920 QUILT-3.006 for Recurrent Medullary Thyroid Cancer https://ClinicalTrials.gov/show/NCT01856920 Active, not recruiting NantCell, Inc. 2019-12-31
NCT01730638 ImmunoTEP for Patients With Medullary Thyroid Carcinoma. https://ClinicalTrials.gov/show/NCT01730638 Completed Nantes University Hospital 2016-12-31
NCT01661179 Evaluate the Safety and Tolerability of Vandetanib in Japanese Patients With Medullary Thyroid Carcinoma https://ClinicalTrials.gov/show/NCT01661179 Completed Sanofi 2013-12-31
NCT01642251 Cisplatin and Etoposide With or Without Veliparib in Treating Patients With Extensive Stage Small Cell Lung Cancer https://ClinicalTrials.gov/show/NCT01642251 Completed National Cancer Institute (NCI) 2016-12-08
NCT01625520 SOM230 Alone or in Combination With RAD001 in Patients With Medullary Thyroid Cancer https://ClinicalTrials.gov/show/NCT01625520 Completed Federico II University 2016-03-31
NCT01563354 3-arm Trial to Evaluate Pasireotide LAR/Everolimus Alone/in Combination in Patients With Lung/Thymus NET - LUNA Trial https://ClinicalTrials.gov/show/NCT01563354 Completed Novartis 2020-02-10
NCT01396382 68Ga-DOTATATE PET Scan in Neuroendocrine Cancer https://ClinicalTrials.gov/show/NCT01396382 Completed Vanderbilt-Ingram Cancer Center 2014-05-31
NCT01365169 Post-op Wellness Program for Pancreatic Cancer Patients That Uses Patient Feedback and Real-time Provider Monitoring https://ClinicalTrials.gov/show/NCT01365169 Recruiting M.D. Anderson Cancer Center 2025-02-25
NCT04280081 A Study of Selpercatinib (LY3527723) in Participants With Advanced Solid Tumors Including RET Fusion-positive Solid Tumors, Medullary Thyroid Cancer and Other Tumors With RET Activation https://ClinicalTrials.gov/show/NCT04280081 Recruiting Eli Lilly and Company 2021-05-31
NCT04122911 Temozolomide for Second-Line Treatment of Neuroendocrine Carcinomas https://ClinicalTrials.gov/show/NCT04122911 Completed National Cancer Institute, Naples 2017-12-30
NCT03992911 Safety and Efficacy of FOLFSIM Plus Toripalimab in the Treatment of Advanced or Metastatic Neuroendocrine Carcinoma https://ClinicalTrials.gov/show/NCT03992911 Recruiting Peking University 2022-06-20
NCT03901378 Pembrolizumab With Chemotherapy in Metastatic or Unresectable High Grade Gastroenteropancreatic or Lung Neuroendocrine Carcinoma https://ClinicalTrials.gov/show/NCT03901378 Recruiting Ochsner Health System 2021-04-30
NCT03858855 Inhaled Essential Oil Effect on Common QOL Concerns During Cancer Treatment https://ClinicalTrials.gov/show/NCT03858855 Completed Ohio State University Comprehensive Cancer Center 2020-04-13
NCT03837977 Second-line Therapy for Patients With Progressive Poorly Differentiated Extra-pulmonary Neuroendocrine Carcinoma https://ClinicalTrials.gov/show/NCT03837977 Recruiting The Christie NHS Foundation Trust 2021-11-01
NCT03834701 Endoscopic Ultrasound-guided RadioFrequency Ablation for the Treatment Pancreatic NeuroEndocrine Neoplasms https://ClinicalTrials.gov/show/NCT03834701 Recruiting Catholic University of the Sacred Heart 2021-06-01
NCT03728361 Nivolumab and Temozolomide in Treating Patients With Recurrent or Refractory Small-Cell Lung Cancer or Advanced Neuroendocrine Cancer https://ClinicalTrials.gov/show/NCT03728361 Recruiting Ohio State University Comprehensive Cancer Center 2021-12-31
NCT03623984 Molecular-Guided Surgery for Pancreatic and GI Neuroendocrine Cancers https://ClinicalTrials.gov/show/NCT03623984 Recruiting University of Alabama at Birmingham 2020-06-07
NCT03600233 Study of CVM-1118 for Patients With Advanced Neuroendocrine Tumors https://ClinicalTrials.gov/show/NCT03600233 Recruiting TaiRx, Inc. 2021-11-30
NCT03591731 Nivolumab +/- Ipilimumab in Patients With Advanced, Refractory Pulmonary or Gastroenteropancreatic Poorly Differentiated Neuroendocrine Tumors (NECs) https://ClinicalTrials.gov/show/NCT03591731 Recruiting Intergroupe Francophone de Cancerologie Thoracique 2021-10-31
NCT03582475 Pembrolizumab With Combination Chemotherapy in Treating Participants With Locally Advanced or Metastatic Small Cell/Neuroendocrine Cancers of Urothelium or Prostate https://ClinicalTrials.gov/show/NCT03582475 Recruiting Jonsson Comprehensive Cancer Center 2020-09-01
NCT03517488 A Study of XmAb®20717 in Subjects With Selected Advanced Solid Tumors https://ClinicalTrials.gov/show/NCT03517488 Recruiting Xencor, Inc. 2020-12-31
NCT01216267 Evaluation of Methods for the Determination of Chromogranin A in Routine Blood Samples https://ClinicalTrials.gov/show/NCT01216267 Completed University of Western Ontario, Canada 2012-01-31
NCT01204476 Cixutumumab, Everolimus, and Octreotide Acetate in Treating Patients With Advanced Low to Intermediate Grade Neuroendocrine Carcinoma https://ClinicalTrials.gov/show/NCT01204476 Completed National Cancer Institute (NCI) 2014-07-31
NCT01155258 Temsirolimus and Vinorelbine Ditartrate in Treating Patients With Unresectable or Metastatic Solid Tumors https://ClinicalTrials.gov/show/NCT01155258 Completed University of Southern California 2013-01-31
NCT01121939 Combination of Bevacizumab, Pertuzumab, and Sandostatin for Adv. Neuroendocrine Cancers https://ClinicalTrials.gov/show/NCT01121939 Completed SCRI Development Innovations, LLC 2015-02-28
NCT01010126 Temsirolimus and Bevacizumab in Treating Patients With Advanced Endometrial, Ovarian, Liver, Carcinoid, or Islet Cell Cancer https://ClinicalTrials.gov/show/NCT01010126 Completed National Cancer Institute (NCI) 2017-03-13
NCT00926640 A Phase I Study of Belinostat in Combination With Cisplatin and Etoposide in Adults With Small Cell Lung Carcinoma and Other Advanced Cancers https://ClinicalTrials.gov/show/NCT00926640 Completed National Institutes of Health Clinical Center (CC) 2017-06-16
NCT00869050 Capecitabine and Temozolomide for Neuroendocrine Cancers https://ClinicalTrials.gov/show/NCT00869050 Completed Columbia University 2013-12-31
NCT01788982 Nintedanib(BIBF1120) in Thyroid Cancer https://ClinicalTrials.gov/show/NCT01788982 Active, not recruiting European Organisation for Research and Treatment of Cancer - EORTC 2019-10-31
NCT02867592 Cabozantinib-S-Malate in Treating Younger Patients With Recurrent, Refractory, or Newly Diagnosed Sarcomas, Wilms Tumor, or Other Rare Tumors https://ClinicalTrials.gov/show/NCT02867592 Recruiting National Cancer Institute (NCI) 2020-09-30
NCT04042714 TAS-102 in Extrapulmonary Neuroendocrine Carcinoma https://ClinicalTrials.gov/show/NCT04042714 Recruiting Baylor Research Institute 2023-08-15
NCT03274258 Phase II Trial of Nivolumab Plus Ipilimumab in Patients With Renal Medullary Carcinoma https://ClinicalTrials.gov/show/NCT03274258 Recruiting M.D. Anderson Cancer Center 2020-07-01
NCT04079712 Testing the Combination of XL184 (Cabozantinib), Nivolumab, and Ipilimumab for Poorly Differentiated Neuroendocrine Tumors https://ClinicalTrials.gov/show/NCT04079712 Recruiting National Cancer Institute (NCI) 2021-10-01
NCT03866382 Testing the Effectiveness of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) With One Anti-cancer Targeted Drug (Cabozantinib) for Rare Genitourinary Tumors https://ClinicalTrials.gov/show/NCT03866382 Recruiting National Cancer Institute (NCI) 2023-02-28
NCT03157128 Phase 1/2 Study of LOXO-292 in Patients With Advanced Solid Tumors, RET Fusion-Positive Solid Tumors, and Medullary Thyroid Cancer https://ClinicalTrials.gov/show/NCT03157128 Recruiting Loxo Oncology, Inc. 2022-03-31
NCT02487095 Trial of Topotecan With VX-970 (M6620), an ATR Kinase Inhibitor, in Small Cell Cancers and Extrapulmonary Small Cell Cancers https://ClinicalTrials.gov/show/NCT02487095 Recruiting National Institutes of Health Clinical Center (CC) 2024-05-31
NCT00780663 Quarfloxin in Patients With Low to Intermediate Grade Neuroendocrine Carcinoma https://ClinicalTrials.gov/show/NCT00780663 Completed Cylene Pharmaceuticals 2010-03-31
NCT00663429 Extension Study of the Safety and Efficacy of Atiprimod Treatment in Neuroendocrine Carcinoma https://ClinicalTrials.gov/show/NCT00663429 Completed Callisto Pharmaceuticals 2010-03-31
NCT00655655 Everolimus and Vatalanib in Treating Patients With Advanced Solid Tumors https://ClinicalTrials.gov/show/NCT00655655 Completed Mayo Clinic 2009-09-15
NCT00625846 Pazopanib Hydrochloride in Treating Patients With Advanced Thyroid Cancer https://ClinicalTrials.gov/show/NCT00625846 Completed National Cancer Institute (NCI) 2018-12-21
NCT00607113 Avastin (Bevacizumab) and RAD001 (Everolimus) in Advanced Low or Intermediate Grade Neuroendocrine Carcinoma https://ClinicalTrials.gov/show/NCT00607113 Completed M.D. Anderson Cancer Center 2011-10-31
NCT00514046 Vandetanib to Treat Children and Adolescents With Medullary Thyroid Cancer https://ClinicalTrials.gov/show/NCT00514046 Active, not recruiting National Institutes of Health Clinical Center (CC) 2019-12-10
NCT00511862 TheraSphere for the Treatment of Liver Metastases https://ClinicalTrials.gov/show/NCT00511862 Completed BTG International Inc. 2011-03-31
NCT00454363 Pazopanib Hydrochloride in Treating Patients With Advanced Neuroendocrine Cancer https://ClinicalTrials.gov/show/NCT00454363 Completed National Cancer Institute (NCI) 2014-03-31
NCT00423254 Safety and Immune Response to a Multi-component Immune Based Therapy (MKC1106-PP) for Patients With Advanced Cancer. https://ClinicalTrials.gov/show/NCT00423254 Completed Mannkind Corporation 2009-09-30
NCT00410761 An Efficacy Study Comparing ZD6474 to Placebo in Medullary Thyroid Cancer https://ClinicalTrials.gov/show/NCT00410761 Active, not recruiting Sanofi 2009-07-31
NCT00390325 Sorafenib Tosylate in Treating Patients With Metastatic, Locally Advanced, or Recurrent Medullary Thyroid Cancer https://ClinicalTrials.gov/show/NCT00390325 Active, not recruiting National Cancer Institute (NCI) 2017-01-30
NCT00388063 Safety and Efficacy of Atiprimod Treatment for Patients With Low to Intermediate Grade Neuroendocrine Carcinoma https://ClinicalTrials.gov/show/NCT00388063 Completed Callisto Pharmaceuticals NA
NCT00381641 Sunitinib Malate in Treating Patients With Thyroid Cancer That Did Not Respond to Iodine I 131 and Cannot Be Removed by Surgery https://ClinicalTrials.gov/show/NCT00381641 Active, not recruiting National Cancer Institute (NCI) 2016-12-31
NCT00363051 Safety/Efficacy of Everolimus in Adults With Advanced Pancreatic Neuroendocrine Cancer Not Responsive to Chemotherapy https://ClinicalTrials.gov/show/NCT00363051 Completed Novartis 2008-01-31
NCT00358956 A Study To Assess ZD6474 (ZACTIMAâ„¢) Monotherapy In Locally Advanced or Metastatic Hereditary Medullary Thyroid Cancer https://ClinicalTrials.gov/show/NCT00358956 Completed Sanofi 2008-01-31
NCT00353015 Irinotecan and Cisplatin for High Grade Neuroendocrine Carcinoma of the Gastrointestinal Tract https://ClinicalTrials.gov/show/NCT00353015 Completed M.D. Anderson Cancer Center 2007-12-31
NCT00193531 Paclitaxel, Carboplatin, and Oral Etoposide Followed by Weekly Paclitaxel in High Grade Neuroendocrine Carcinoma https://ClinicalTrials.gov/show/NCT00193531 Completed SCRI Development Innovations, LLC 2007-01-31
NCT00113360 RAD001 Plus Octreotide Depot in Metastatic or Unresectable Low Grade Neuroendocrine Carcinoma https://ClinicalTrials.gov/show/NCT00113360 Completed M.D. Anderson Cancer Center 2009-07-31
NCT00093782 Temsirolimus in Treating Patients With Metastatic Neuroendocrine Carcinoma https://ClinicalTrials.gov/show/NCT00093782 Completed National Cancer Institute (NCI) 2011-04-30
NCT00003549 S9716: Combination Chemotherapy in Treating Patients With Merkel Cell Cancer https://ClinicalTrials.gov/show/NCT00003549 Completed Southwest Oncology Group 2001-09-30
NCT00079131 Oblimersen in Treating Patients With Merkel Cell Carcinoma https://ClinicalTrials.gov/show/NCT00079131 Completed National Cancer Institute (NCI) 2007-01-31
NCT00004922 Irinotecan in Treating Patients With Advanced Neuroendocrine Tumors https://ClinicalTrials.gov/show/NCT00004922 Completed Memorial Sloan Kettering Cancer Center 2002-06-30
NCT00068783 S0331: Imatinib Mesylate in Treating Patients With Metastatic or Unresectable Merkel Cell Cancer https://ClinicalTrials.gov/show/NCT00068783 Completed National Cancer Institute (NCI) 2007-06-30
NCT00019786 Isolated Hepatic Perfusion With Melphalan in Treating Patients With Primary Unresectable Liver Cancer or Liver Metastases https://ClinicalTrials.gov/show/NCT00019786 Completed National Institutes of Health Clinical Center (CC) NA

Observational Studiess

#If less then 500 studies

nct_id brief_title link overall_status source primary_completion_date
NCT04216732 Natural History of Medullary Thyroid Cancer to Inform Advanced Disease Management https://ClinicalTrials.gov/show/NCT04216732 Recruiting M.D. Anderson Cancer Center 2022-09-01
NCT03305133 Evaluation of PD-L1 (Programmed Death-Ligand 1) Tumor Expression in Patients With Large-cell Neuroendocrine Carcinoma (NEC) https://ClinicalTrials.gov/show/NCT03305133 Completed Groupe Francais De Pneumo-Cancerologie 2018-09-14
NCT02465424 Assessing Quality of Life Tools in Medullary Thyroid Cancer Patients https://ClinicalTrials.gov/show/NCT02465424 Completed Velindre NHS Trust 2017-12-31
NCT01945762 Observational Study to Evaluate Vandetanib in RET -/+ Patients With Metastatic Medullary Thyroid Cancer https://ClinicalTrials.gov/show/NCT01945762 Recruiting Sanofi 2019-09-30
NCT01703650 Role of Perfusion CT in Pancreatic Cancer https://ClinicalTrials.gov/show/NCT01703650 Active, not recruiting Seoul National University Hospital 2015-12-31
NCT01603004 Potential Molecular Predictors of Response to Novel Therapies in Metastatic Pancreatic Neuroendocrine Tumors https://ClinicalTrials.gov/show/NCT01603004 Completed Memorial Sloan Kettering Cancer Center 2019-06-24
NCT01424878 Study of Molecular Pathways in Medullary Thyroid Carcinoma and Correlation of Molecular Data With Clinical Behavior of the MTC in Individuals Patients https://ClinicalTrials.gov/show/NCT01424878 Completed National Institutes of Health Clinical Center (CC) NA
NCT04331912 PFS and OS of Patients With Advanced Neuroendocrine Cancer (NEN) After Systemic Treatment https://ClinicalTrials.gov/show/NCT04331912 Active, not recruiting University of Warmia and Mazury 2022-12-31
NCT04069299 Use of 68Ga-dotatate PET Scan in Neuroendocrine Carcinoma of the GI Tract https://ClinicalTrials.gov/show/NCT04069299 Active, not recruiting H. Lee Moffitt Cancer Center and Research Institute 2020-12-01
NCT03884179 Diagnosis of PCL With EUS-FNA and Cross-sectional Imaging - A Report of Accuracy https://ClinicalTrials.gov/show/NCT03884179 Active, not recruiting Sahlgrenska University Hospital, Sweden 2017-12-01
NCT03774862 Clinicopathological Importance of Colorectal Medullary Carcinoma: Retrospective Cohort Study https://ClinicalTrials.gov/show/NCT03774862 Completed V.K.V. American Hospital, Istanbul 2017-12-31
NCT03643055 18F-Fluorocholine PET/CT in Medullary Thyroid Cancer https://ClinicalTrials.gov/show/NCT03643055 Recruiting University Medical Centre Ljubljana 2020-09-03
NCT03616431 Pancreatic Cancer Dietary Assessment Study https://ClinicalTrials.gov/show/NCT03616431 Recruiting The Christie NHS Foundation Trust 2022-05-31

Registries

#If less then 500 registries

nct_id brief_title link overall_status source primary_completion_date
NCT02270567 RegisterNET - A Registry for Neuroendocrine Tumors in the USA https://ClinicalTrials.gov/show/NCT02270567 Active, not recruiting Wren Laboratories LLC 2018-03-31
NCT01511393 An Active Surveillance Program for Cases of Medullary Thyroid Carcinoma (MTC) https://ClinicalTrials.gov/show/NCT01511393 Enrolling by invitation United BioSource, LLC 2035-12-31